RxDoctor Payments DataLook up a doctor →

Salil Patel, MD

Interventional Cardiology · Jacksonville, FLNPI 1083666366

Payments from drug & device makers

$305,910in general payments, 2019–2025

Across 474 payments — averaging $645.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$284K
  • Abiomed$4K
  • Penumbra, Inc.$4K
  • Angiodynamics, Inc.$3K
  • Abbott$2K
  • Boston Scientific$1K
  • plus $8K from 46 others

What the payments were for

  • Travel & lodging$1,0174%
  • Food & beverage$19,29682%
  • Education$3,31114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$305,910 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$363,008
Medicare patients
1,553
Services billed
3,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$126,169
XareltoRivaroxaban89$89,783
Repatha SureclickEvolocumab68$59,853
EntrestoSacubitril/Valsartan47$48,892
Metoprolol Succinate108$1,740
Atorvastatin Calcium198$1,704
Ranolazine ErRanolazine11$1,425
ClopidogrelClopidogrel Bisulfate104$1,082
Isosorbide Mononitrate ErIsosorbide Mononitrate68$1,029
Rosuvastatin Calcium63$1,017
Carvedilol64$673
Cilostazol31$632
Amlodipine Besylate73$606
Ezetimibe22$576
Isosorbide Dinitrate14$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$217$126,169149 claims
Johnson & JohnsonXarelto$310$89,78389 claims
NovartisEntresto$332$48,89247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →